PDAC - Pancreatic Ductal Adenocarcinoma

Oncology
0
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Verona Pharma
Verona PharmaUK - London
2 programs
RegisterN/A1 trial
ctDNA analysisN/A1 trial
Active Trials
NCT05845801Recruiting3,000Est. Sep 2052
NCT05853198Recruiting165Est. May 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Verona PharmactDNA analysis
Verona PharmaRegister

Clinical Trials (2)

Total enrollment: 3,165 patients across 2 trials

Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability

Start: Dec 2022Est. completion: May 2026165 patients
N/ARecruiting

Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

Start: Dec 2022Est. completion: Sep 20523,000 patients
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 3,165 patients
1 companies competing in this space